cicaprost

RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer

Also Known As:

13,14-didehydro-16,20-dimethyl-3-oxa-18,18,19,19-tetradehydro-6-carbaprostaglandin I2; 5-(7-hydroxy-6-(3-hydroxy-4-methylnona-1,6-diynyl)-bicyclo(3.3.0)octan-3-yliden)-3-oxapentanoic acid; ZK 96480; ZK-96480; cicaprost dihydrochloride

Networked: 37 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jones, Robert L: 2 articles (09/2003 - 10/2002)
2.	Kan, Kelvin K W: 2 articles (09/2003 - 10/2002)
3.	Rudd, John A: 2 articles (09/2003 - 10/2002)
4.	Poloso, Neil J: 1 article (01/2017)
5.	Vu, Chau: 1 article (01/2017)
6.	Wang, Jenny W: 1 article (01/2017)
7.	Gryglewski, Ryszard J: 1 article (01/2008)
8.	Fujino, Takayuki: 1 article (07/2005)
9.	Hara, Akiyoshi: 1 article (07/2005)
10.	Karibe, Hideji: 1 article (07/2005)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1997 - "Whereas starting treatment with Cicaprost on the day of tumor implantation was a characteristic feature of our previous investigations, the present study focused on the antimetastatic potency of Cicaprost in animals with established tumor growth. " 01/01/1996 - "As primary tumor growth in vivo or proliferation in vitro remained unchanged by cicaprost, its mode of action seems to be related to one or more mechanisms of the metastatic process. " 07/17/1995 - "Results also indicate that direct effects on tumor cells may contribute to the anti-metastatic action of cicaprost in spontaneously metastasizing tumors." 07/17/1995 - "In addition to its inhibitory potential in animals with advanced tumor disease, cicaprost showed anti-metastatic action when used in peri-operative treatment of animals whose primary tumors had been removed. " 07/17/1995 - "Start of treatment with cicaprost immediately before tumor implantation was a characteristic feature of our previous investigations. "
2.	Neoplasm Metastasis (Metastasis) 07/17/1995 - "Using different treatment schedules, a pronounced reduction of the number of lung metastases was achieved by administration of cicaprost until the end of the experiment (from day 5 to day 35), whereas short-term treatments (from day 5 to day 15 or to day 25) were without significant effect. " 01/01/1994 - "Moreover, metastasis to the contralateral axillary lymph node was completely inhibited by Cicaprost at all three doses tested. " 01/01/1994 - "Whereas the median number of lung metastases in the controls was greater than 1000, Cicaprost at a dose of 0.1 mg/kg reduced the number of lung metastases to between 11 and 100. " 01/01/1994 - "Cicaprost given in daily doses of 0.01, 0.03 and 0.1 mg/kg orally, reduced the number of lung metastases in a dose-dependent manner. " 11/01/1991 - "Cicaprost in all doses tested reduced the number of liver metastases in a statistically significant manner. "
3.	Neoplasm Micrometastasis 01/01/1995 - "Our own studies have shown that Cicaprost, a stable prostacyclin analogue, prevents metastasis if given continuously from the day of tumor implantation, and is also effective in reducing metastasis if treatment is begun following surgical removal of the primary tumor, when micrometastases are already present."
4.	Hypercholesterolemia 10/01/1993 - "Antiatherosclerotic effects of oral cicaprost in experimental hypercholesterolemia in rabbits." 01/01/1992 - "Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia." 01/01/1992 - "Oral cicaprost resulted in a significantly reduced aortic atheromatous plaque formation and partially prevented hypercholesterolemia-induced impairment of endothelium-dependent relaxations. " 01/01/1992 - "Cicaprost treatment (5 micrograms/kg x d) largely prevented the hypercholesterolemia-related impairment of coronary vasodilation and nitric oxide release. " 01/01/1992 - "Oral treatment of cholesterol-fed rabbits with the PGI2 mimetic cicaprost largely reduces hypercholesterolemia-induced platelet and neutrophil hyperreactivity. "
5.	Atherosclerotic Plaque (Atheroma) 01/01/1992 - "Oral cicaprost resulted in a significantly reduced aortic atheromatous plaque formation and partially prevented hypercholesterolemia-induced impairment of endothelium-dependent relaxations. " 10/01/1993 - "The efficacy of the oral prostacyclin mimetic cicaprost in preventing atheromatous plaque formation was studied in an in vivo model of experimental hypercholesterolemia. "

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Cyclodextrins
3.	Acids
4.	Abciximab (ReoPro)
5.	Iloprost (Ventavis)
6.	Cytostatic Agents
7.	Aspirin (Acetylsalicylic Acid)
8.	butaprost
9.	fluprostenol
10.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)

Related Therapies and Procedures

1.	Therapeutics
2.	Lasers (Laser)
3.	Intravenous Infusions
4.	Oral Administration